LTE wireless data speeds are impressing new iPhone 5 and Android phone customers all across the U.S., but some of the speeds are mind-blowing. read more
See more here:
iPhone 5 with LTE: Customer gets near-50 Mbps download speed
Monthly Archives: October 2012
Penn Translational Medicine Researcher Named 2012 Louis and Arthur Lucian Award Recipient
PHILADELPHIA - Garret FitzGerald, MD, FRS, director of the Institute for Translational Medicine and Therapeutics and chair, Department of Pharmacology, at the Perelman School of Medicine, University of Pennsylvania, has been named the 2012 recipient of the Louis and Arthur Lucian Award, given by McGill University, Montreal, Canada. He is cited for his ground-breaking work on cardiovascular disease. The award consists of a $CAN60,000 prize and one-to-two week professional visit to McGill to give a formal Lucian Lecture, to have interchanges with members of the McGill community, and possibly to undertake a research collaboration with McGill investigators in the field of circulatory diseases.
FitzGerald, also professor of Medicine and Pharmacology and the McNeil Professor in Translational Medicine and Therapeutics, takes an integrative approach to studying the mechanisms of drug action and is known internationally for his work on eicosanoids and related lipid mediators. His research contributed fundamentally to the development of low-dose aspirin as a preventive approach to heart disease. His group was the first to predict and then explain mechanistically the cardiovascular hazard from NSAIDs. His team has also contributed substantially to the understanding of the importance of peripheral clocks in the regulation of cardiovascular and metabolic function.
I am honored to receive the Lucian Award and humbled to follow so many distinguished scientists who have received this distinction, said FitzGerald. It reflects on the enthusiasm, creativity and hard work of so many colleagues with whom I have been privileged to work over many years.
The Louis and Artur Lucian Award was established through a bequest to McGill University under the will of the late Olga Leibovici to honor the donor's two brothers, and was conferred for the first time in 1978. The Award is designed to honor outstanding research in the field of circulatory diseases by a scientific investigator or group of investigators whose contribution to knowledge in this field is deemed worthy of special recognition. As per the terms of the bequest, the work of the nominee must be current.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
See the rest here:
Penn Translational Medicine Researcher Named 2012 Louis and Arthur Lucian Award Recipient
Taken a medicine chest inventory?
Published: Sept. 30, 2012 at 11:18 PM
NEW YORK, Sept. 30 (UPI) -- A U.S. public health campaign has been started to challenge people to take part in a five-step effort to reduce the risk of prescription drug abuse.
Angelo M. Valente, chief executive officer of American Medicine Chest Challenge, said the campaign aims to prevent prescription drug abuse and provide safe disposal options for prescription and over-the-counter drugs.
"Recent American Medicine Chest Challenge initiatives, such as the creation of the National Online Directory of Permanent Prescription Drug Collection Boxes and the release of the American Medicine Chest Challenge Rx Drop mobile application, have made taking the challenge and the disposing of unused, unwanted and expired medicine much easier for American families," Valente said in a statement.
The program challenges people to:
-- Take inventory of your prescription and over-the-counter medicine.
-- Secure your medicine chest.
-- Dispose of your unused, unwanted, and expired medicine in your home or at an approved disposal site.
-- Take your medicine(s) exactly as prescribed.
-- Talk to your children about the dangers of prescription drug abuse.
Read the rest here:
Medicine Hat teen killer sentence reviewed
Canada's youngest multiple killer appeared by closed circuit television in an Alberta courtroom Monday for an update on her progress.
The teen killed her parents and eight-year-old brother in 2006 when she was 12 years old. The now 18-year-old known only as J.R. was convicted in 2007 of three counts of first-degree murder.
J.R. is currently living alone while working and taking classes, Medicine Hat court heard Monday. She is responding positively to treatment, expresses remorse experts consider genuine, and is assessed at a low risk to reoffend, according to a report read out in court.
"You are doing well. Keep up the good work, said Justice Scott Brooker.
J.R.s sentence, known as an intensive rehabilitative custody and supervision (IRCS), had been reviewed by the Court of Queens Bench every six months. However Brooker decided Monday that she can now have her sentence reviewed once a year.
We are seeing she is in the community, she is starting to get her feet on the ground and build a life for herself, said defence lawyer Katherine Beyak outside court.
J.R. started her 10-year-sentence at a psychiatric hospital but was released in the fall of 2011 to begin her integration into society. She moved to a group home and started studying at a post-secondary institution. J.R. has three and a half years left on her conditional sentence.
J.R. and her then-boyfriend Jeremy Steinke, who was 23, killed the three victims at J.R.s family home in the southern Alberta town of Medicine Hat.
Steinke was sentenced to life in prison for his part in the killings, which the pair carried out because the parents didn't approve of their relationship.
Read the original post:
Third Rock Ventures Appoints Personalized Medicine Expert Felix W. Frueh, Ph.D., as Entrepreneur-in-Residence
BOSTON--(BUSINESS WIRE)--
Third Rock Ventures, LLC, a venture capital firm focused on building life sciences companies, today announced that Felix W. Frueh, Ph.D., has joined Third Rock as an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.
We are pleased to welcome Felix to our growing team of industry leaders, said Alexis Borisy, partner of Third Rock Ventures. Since the founding of Third Rock, we have been dedicated to launching companies focused on personalized medicine, and Felix is the ideal person to help us continue to grow and develop those companies in our portfolio and discover new opportunities to invest in the space.
Dr. Frueh is a thought leader in personalized medicine with 15 years of R&D, management and policy experience. Most recently, Dr. Frueh served as president of the Medco Research Institute, leading Medcos real-world, outcomes-oriented research initiatives and collaborations after having formed Medcos personalized medicine research and development organization. Prior to joining Medco, Dr. Frueh was associate director for genomics at the U.S. Food and Drug Administration (FDA), where he built and led the core genomics review team in the Center for Drug Evaluation and Research (CDER) and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Before joining the FDA, he held senior positions at several biotechnology companies. Dr. Frueh has been a member of various working groups on genetics and genomics at the FDA and Department of Health and Human Services (DHHS). He serves on the board of the Personalized Medicine Coalition and is also a board member at Enterome Biosciences. He is an adjunct faculty member at the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina (UNC) and held faculty appointments in the Departments of Pharmacology and Medicine at Georgetown University in Washington, D.C. He was a postdoctoral fellow at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.
Throughout my career, I have had the opportunity to see new technologies and innovative approaches in personalized medicine make an impact on the lives of patients, said Dr. Frueh. I believe that Third Rocks approach to investing in cutting edge science has the potential to make a tremendous difference, and I look forward to being a part of that effort.
About Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $800 million and two funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients. The firm has assembled a team with deep expertise and a proven track record of building respected and successful life sciences companies. With decades of complementary, cross-functional operational and leadership experience, the Third Rock team actively engages with its portfolio companies to provide hands-on strategy and experience to successfully launch companies with the best vision, science, operations, people and culture. With offices in Boston, MA and San Francisco, CA, Third Rock is well positioned geographically to closely collaborate with its portfolio companies to achieve their goals. To learn more about Third Rock and its portfolio companies, please visit http://www.thirdrockventures.com.
Current Third Rock Portfolio Companies
Ablexis, Afferent Pharmaceuticals, Agios Pharmaceuticals, Alcresta, Allena Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly & Co. in 2010), bluebird bio, Blueprint Medicines, Constellation Pharmaceuticals, CytomX Therapeutics, DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, Ember Therapeutics, Foundation Medicine, Global Blood Therapeutics, Igenica, Kala Pharmaceuticals, Lotus Tissue Repair, MyoKardia, Nine Point Medical, PanOptica Pharmaceuticals, Rhythm Pharmaceuticals, SAGE Therapeutics, Seventh Sense Biosystems, Taris Biomedical, Topica Pharmaceuticals, Warp Drive Bio and Zafgen.
See more here:
Never Forget to Take Your Medicine Again
Medication non-adherence is a costly problem for our nations health-care system--to the tune of $290 billion a year.
Forgetfulness is often cited as the top reason people dont follow their medication plans, and the problem only gets worse for patients on multiple drugs.
To help keep patients on track with the treatments, a slew of apps and devices have hit the market. From web-based reminders to pill organizers, heres a look at four new tools designed to help patients adhere to their treatment plans.
MedMinder
The MedMinder pill dispenser works in conjunction with the Internet to keep track of when medicine is taken to promote adherance.
Heres how it works: Place the pills in the dispenser compartments and then go to MedMinders website to detail when the medicine should be taken. The site will then send reminders when its time to take the pills. The alerts come in the form of a light, sound alert, phone call, text or email. The device will even notify designated caregivers or family members when a medication isnt taken. The pill dispenser and reminder service costs $39.99 a month, and the device needs to be returned to the company.
Digestible Digital Pills
Be on the look out for new digestible pills with built in sensors to track when a user swallow medicine.
Some may be turned off by this new digital pill, but the FDA has green lighted Proteus Digital Health to work to digitize drugs to treat diabetes, the central nervous system and transplants.
According to Proteus Digital Health, each pill will contain a sensor that can communicate with its digital health feedback system to provide information about how users take the prescription drugs and how the body is responding to it. Proteus claims that more than 50% of people dont get the complete benefits from their pharmaceuticals because they take the wrong dose or inconsistently take their medicine.
Continued here:
Personalized Medicine's Transformation of Healthcare Accelerates
SAN FRANCISCO, CA--(Marketwire - Oct 1, 2012) - The life sciences sector continued to outperform the broader markets in September, but developments during the month were notable for highlighting the acceleration of the transformation of healthcare through personalized medicine, Burrill & Company says.
"Our healthcare system is dysfunctional and has largely been unchanged through human history in its episodic approach that focuses on treating the symptoms of illness," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm. "Although personalized medicine's transformation of healthcare is an evolutionary rather than a revolutionary process, the events of the past month point to a rapid acceleration of efforts to make medicine personalized, predictive, and pre-emptive and promises to bend the cost-curve of healthcare in a meaningful way."
The University of Texas MD Anderson Cancer Center's announced an ambitious $3 billion Cancer Moon Shots Program, which seeks to develop new diagnostics, devices, drugs, and policies to detect, prevent, and treat cancer by capitalizing on the convergence of low-cost sequencing, artificial intelligence, and other emerging technologies.
September also saw a number of developments on the sequencing front. Chinese sequencing giant BGI-Shenzhen announced a $117.6 million acquisition of the struggling next-generation sequencing company Complete Genomics. Mountain View, California-based Complete Genomics, which has been working to provide whole genome sequencing through a service-based business model, announced a restructuring in June that included a shift in focus to the development of clinical applications for its whole genome sequencing service. BGI-Shenzhen provides deep pockets that should accelerate the clinical applications of Complete Genomic's technology.
Complete Genomics' larger competitors also announced developments that should accelerate the clinical utility of genomic sequencing. Life Technologies began shipping its low-cost Ion Proton sequencing system. The company said the chip-based system cost about a third of genome scale sequencing systems that rely on light to read a genome. The device sits on a desktop and can sequence exomes and transcriptomes in two to four hours at a cost of $1,000 per run. Life Technologies next expects to release a second-generation chip for the system around the end of the first quarter of 2013 that will be able to sequence the human genome in a few hours for $1,000.
At the same time, the genetic sequencing tools company Illumina and the non-profit healthcare system Partners Healthcare announced an agreement to provide geneticists and pathologists networking tools and infrastructure to report and interpret data from genetic sequencing. By pairing Illumina's expertise in sequencing with Partners Healthcare's understanding of what's needed for clinical utility, the two hope to leverage each other's strengths to deliver a comprehensive sequencing and clinical reporting solution.
Others are also taking steps to apply new personalized medicine approaches to clinical care. The Big Data analytics company GNS Healthcare in September announced a new program with the healthcare insurance company Aetna to use GNS' supercomputing capabilities to help identify Aetna members at risk for heart and metabolic disorders that can result in stroke, heart attack or diabetes, earlier than it does today. GNS will develop data-driven models that will define a person's risk for developing metabolic syndrome using Aetna claims data as well as health records. A separate agreement between GNS and the contract research organization Covance seeks to improve drug development by using GNS' modeling to predict the safety and efficacy of a drug candidate against different patient characteristics.
On the research side, September also saw major advances in understanding the genetics underlying disease. The Encode Project, an ambitious international effort to characterize and publish all of the functional elements in the human genome, found that the 80 percent of DNA once thought of as "junk" actually plays a critical role in regulating genes and can also play a part in the onset of disease. Researchers identified more than 4,000 switches involved in gene regulation. The findings not only create a new understanding of the role of some 80 percent of DNA once thought to serve no functional role, but also provide a new source of potential targets for drugs, and new insight into how genes are regulated and how people become ill.
Separately, a collaborative effort funded by the National Cancer Institute and the National Human Genome Research Institute, using data generated as part of The Cancer Genome Atlas, has provided a new understanding of the four major subtypes of breast cancer and finds shared genetic features between the form of breast cancer known as "Basal-like" or "Triple Negative" breast cancer and serious ovarian cancer. The findings will lead to researchers comparing treatments and outcomes for patients with the two forms of cancer and could lead to new therapeutic approaches.
"With new research findings we are reminded about how much we still don't know, but also of the rapid progress we are making," says Burrill. "We are seeing real examples of personalized medicine moving from idea to practice in meaningful ways."
View post:
Personalized Medicine's Transformation of Healthcare Accelerates
Popular Migraine Medicine Quickly Absorbed When Delivered With Novel Breath Powered OptiNose Bi-Directional™ Nasal …
YARDLEY, Pa., Oct. 2, 2012 /PRNewswire/ -- OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex liquid nasal spray (20mg).
To view the multimedia content, please click: http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
(Photo: http://photos.prnewswire.com/prnh/20121002/MM84415 )
In addition to showing better early drug absorption than Imitrex nasal spray, the study demonstrated in healthy volunteers that a 16mg dose of OptiNose sumatriptan 84% less drug than Imitrex 100 mg tablet delivered three times more drug into the blood within the first 15 minutes than the oral tablet. During migraine attacks there is a delay in stomach emptying which slows and reduces the reliability of absorption of sumatriptan pills even more, a problem avoided by effective administration of drug in the nose.
"Migraines affect nearly 30 million Americans. People often experience symptoms that progress rapidly, making it difficult to initiate or complete daily activities. Even with the wide range of current medications, many migraine sufferers are dissatisfied and searching for new treatments that provide faster relief with fewer side effects," said Ramy A. Mahmoud, M.D., M.P.H., Chief Operating Officer of OptiNose. "These data show the OptiNose technology has the capability of more efficiently and effectively delivering medicine into the blood in the important first 15 to 30 minutes. Now that OptiNose has demonstrated better drug delivery, we are working on the clinical program to show how improved drug delivery translates into meaningful benefits for migraine sufferers."
To assess the clinical relevance of these study findings, OptiNose has already begun enrolling patients in a head-to-head study comparing OptiNose nasal sumatriptan powder (16 mg) to the most widely prescribed headache medicine, sumatriptan tablets (100 mg) the medicine in Imitrex. The study, called the COMPASS trial, will assess early headache relief (15 and 30 minutes after the first dose of medicine), as well as headache relief at other time points and various other measures of efficacy and treatment related side-effects. The trial is currently enrolling. Click here or visit http://www.optinose.com for additional information.
Additional Study InformationThis randomized, single-dose, four-way cross-over study assessed the pharmacokinetic (PK) profile of sumatriptan intranasal powder (16 mg) administered using the breath powered OptiNose Bi-Directional drug delivery device compared to Imitrex subcutaneous injection (6 mg), nasal spray (20 mg) and oral tablets (100 mg) in 20 healthy adult volunteers. Standard PK assessments including peak plasma concentration, drug exposure over time and total drug exposure were measured.
In addition to the above results, the study found patients taking 16mg sumatriptan with OptiNose technology had substantially less total exposure to drug than those given a standard dose of Imitrex 100 mg oral tablet. Total drug exposure for Imitrex tablets was more than four times higher than with OptiNose nasal powder delivery. Total serum exposure was similar between 16mg delivered with an OptiNose Bi-Directional device and 20mg Imitrex nasal spray, though absorption was notably faster with OptiNose. Total drug exposure was twice as high with Imitrex injection, a treatment option generally associated with a notably different side-effect profile.
There were no serious adverse events (SAEs) or discontinuations due to adverse events (AEs). The most commonly reported adverse events were mild nausea (3 reports each following Imitrex injection and tablets) and mild flushing (4 reports following Imitrex injection).
Phase III TARGET StudyA phase III trial called the TARGET study was initiated in January to prove the efficacy and safety of OptiNose delivery of low-dose sumatriptan. Results will be available later this month, specifically assessing the ability of OptiNose sumatriptan delivered with breath powered Bi-Directional technology to offer rapid pain relief, meaningful headache relief and other measures.
See the article here:
Renowned Emergency Physician, Dr. Steven J. Davidson Joins Emergency Medicine Business Intelligence as its Chief …
NEW YORK, Oct.1, 2012 /PRNewswire/ --Emergency Medicine Business Intelligence, Inc. (EMBI) has announced that Steven J. Davidson, MD, MBA, FACEP a 35-year veteran of Emergency Medicine and recognized leader in health care informatics joined EMBI as Chief Medical Officer in which role he will lead the EMBI Medical Advisory Board.
Dr. Davidson will continue serving as Senior Vice President and Chief Medical Informatics Officer at Maimonides Medical Center in Brooklyn, N.Y. where he was Founding Chair of Emergency Medicine, 1995-2010. Trained in Emergency Medicine's earliest days, Dr. Davidson has subsequently engaged nearly all aspects of emergency medicine. His work with leading thinkers in quality improvement drove his pursuit of an MBA at The University of Pennsylvania Wharton School, earned in 1989. Having accomplished much of his vision at Maimonides, he shared those principles in a monthly "Leadership Outlook" column from 2000-2004 in Emergency Medicine News and in other publications since.
"Dr. Davidson has joined EMBI because our solution implements and extends his vision of leading transformation informed by relevant measures of clinical, operational and financial performance. He appreciates how EMBI's solution turns silos of data into actionable information. Through the Medical Advisory Board he will lead, Dr. Davidson and his colleagues, will provide guidance to EMBI to ensure our solution stays focused on addressing the problems and meeting needs of their peers and the emergency departments they manage," says Scott Richards, EMBI's CEO and Co-Founder.
Davidson comments, "As the ED becomes a progressively more challenging environment for patients and practitioners alike, EMBI's simplified data management empowers those engaged ED leaders who are devoted to improving clinical, operational and financial performance while gaining the opportunity for improved service quality for patients and a more pleasant, effective working environment for practitioners and staff."
Jonathan Rothman, EMBI's CTO and Co-Founder comments, "We grew up in this space; starting at about the same time Dr. Davidson arrived in Brooklyn. Over the years we've had the honor of meeting and working with many Emergency Medicine leaders. Dr. Davidson stands out among them for his thought leadership, objective accomplishments and his development of Emergency Medicine leaders. We are excited he is joining our team and look forward to his contributions."
Emergency Medicine Business Intelligence, Inc.
Emergency Medicine Business Intelligence, Inc. is an innovator in health care business intelligence. EMBI provides real-time and retrospective web-based performance dashboards and key metric analytics for hospital emergency departments. Leveraging the Balanced Scorecard business processes, EMBI solutions benchmark and monitor every aspect of an emergency department, including patient care, turn-around-times, productivity, utilization, satisfaction, revenue cycle, and risk. EMBI uses a clean and intuitive user interface to present how the emergency department's KPIs are trending in real-time, last month, over the past 13 months and benchmarked against its peers. More information about EMBI can be found at http://www.embiondemand.com.
View post:
Translational Regenerative Medicine: Market Prospects 2012-2022
NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Translational Regenerative Medicine: Market Prospects 2012-2022
Report Details
New study shows you commercial potential of regenerative treatments
See what the future holds for translational regenerative medicine. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product and regional level to 2022.
There you investigate the most lucrative areas in that research field, industry and market. Discover prospects for tissue-engineered products, stem cell treatments and gene therapy.
We pack our study with information and analysis to help your work and save you time:
Access to present and predicted trends, with commercial opportunities and prospects revealed
Data and discussions - including our revenue forecasts to 2022 - for your research, analyses and decision making
Read the rest here:
Translational Regenerative Medicine: Market Prospects 2012-2022
Steven Rose, M.D., Named Dean of Mayo School of Graduate Medical Education
Monday, October 01, 2012
ROCHESTER, Minn. Steven Rose, M.D., has been named dean of Mayo School of Graduate Medical Education at Mayo Clinic. He succeeds Mark Warner, M.D., who served as dean from 2006 until his appointment as executive dean for education in July 2012. Dr. Rose's appointment is effective immediately. He will be responsible for graduate medical education activities throughout Mayo Clinic.
Dr. Rose began his career at Mayo as a physician in the Department of Anesthesiology in 1988. He was appointed vice dean of Mayo School of Graduate Medical Education in 2007 and became a professor in the College of Medicine, Mayo Clinic last year. He has received several awards, including the Resident Education Award, the Distinguished Clinician Award and the Distinguished Service Award in the Department of Anesthesiology.
Dr. Rose is an author, researcher and educator whose interests focus on orthopedic and thoracic anesthesia and medical education. He serves as an editor or reviewer for several journals.
Mayo Clinic educates medical and science professionals through five schools: Mayo Medical School, Mayo Graduate School, Mayo School of Health Sciences, Mayo School of Graduate Medical Education and Mayo School of Continuous Professional Development. Mayo School of Graduate Medical Education was established in 1915. About 1,500 residents and fellows are enrolled in more than 250 programs representing virtually every medical specialty.
###
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.
Here is the original post:
Steven Rose, M.D., Named Dean of Mayo School of Graduate Medical Education
ADVANCE Medical Expands Operations Into Mexico and Strengthens Agreement With ZELTIQ(R) Aesthetics
PALO ALTO, CA and SAO PAULO, BRAZIL and MEXICO CITY--(Marketwire - Oct 2, 2012) - ADVANCE Medical, a company formed in 2011 by U.S. and Latin American investors with the goal of becoming the Latin American commercial partner-of-choice for innovative medical technology companies, announced today it has expanded its partnership with ZELTIQ Aesthetics ( NASDAQ : ZLTQ ), developer of the CoolSculpting System. Under the terms of the expanded agreement, ADVANCE Medical has increased the exclusivity period of the agreement and added Mexico as an exclusive territory.
ADVANCE Medical also announced the addition of Francisco Demesa as General Manager for Mexico Operations. Francisco comes from AstraZeneca, where he spent 6 years in commercial roles both in the United States as well as in various countries in Latin America. In his most recent role at AstraZeneca, Francisco was Marketing Director for Mexico where he was responsible for all medical brands, including the launches of Nexium pediatric, Onglyza, Brilinta and "Save Women's Heart" initiative. Francisco also headed a number of commercial efforts for AstraZeneca in Argentina, Chile, Venezuela and Colombia. Prior to AstraZeneca, Francisco spent 10 years in sales and marketing for Unilever, BAT and DuPont. He earned his B.S. in Marketing from Tec de Monterrey and his M.B.A. from the Harvard Business School.
"ADVANCE Medical has demonstrated that its model can be quite successful based on the company's performance with CoolSculpting in Brazil," stated Mark Foley, President and Chief Executive Officer of ZELTIQ Aesthetics. "ADVANCE Medical has built in Brazil a large installed base of CoolSculpting Systems and won an award from ZELTIQ at the latest American Academy of Dermatology annual meeting for generating the highest consumable sales per system in the world during 2011. We are pleased to strengthen our relationship as ADVANCE Medical launches CoolSculpting in Mexico."
"The expansion of our collaboration with ZELTIQ is an important step towards our stated strategy of forging closer ties with our partners, and validation that we can enter a highly competitive and relationship-driven market and be quite successful by hiring the best people, building the appropriate infrastructure, and making the right investments," stated Fred Aslan, M.D., founder and Chief Executive Officer of ADVANCE Medical. "With the addition of Francisco Demesa, we are in a strong position to continue our geographical expansion as we strive to become the Latin American partner-of-choice for truly innovative companies."
Formed in 2011, ADVANCE Medical raised a US$6 million Series A financing led by Venrock and Latin American institutional investors and angels to commercialize leading innovative medical technologies in Brazil and other countries in Latin America. The Company specializes in commercializing products that require a more sophisticated sales and marketing approach. ADVANCE Medical employs experienced executives from the pharmaceutical and medical device industries who have experience launching and commercializing products in Latin America. By working closely with the technology originator, ADVANCE Medical is able to gain a more thorough understanding of products and to build a customized commercial strategy and infrastructure on the ground for a launch or further commercial expansion. Brazil and Mexico have the seventh and thirteenth largest nominal GDP (Gross Domestic Product) in the world respectively with a combined population of over 300 million people. Latin America healthcare product imports have been growing at double digit rates, offering attractive markets for companies with innovative products and services.
About ADVANCE Medical
ADVANCE Medical is a commercial-focused company with offices in Palo Alto, Sao Paulo and Mexico City whose mission is to become the partner-of-choice for innovative global medical technology companies looking to commercialize their products in Latin America. The Company specializes in commercializing products that require a more sophisticated sales and marketing approach targeting select physician segments. ADVANCE Medical employs experienced executives from the pharmaceutical and medical device industries who have experience launching and commercializing products in Latin America. The Company's first commercial product is CoolSculpting by ZELTIQ Aesthetics, the first aesthetic medical device approved by the U.S. Food and Drug Administration (FDA) for the non-invasive reduction of subcutaneous fat utilizing a clinically-proven technique that employs cold to selectively destroy fat cells.
View original post here:
ADVANCE Medical Expands Operations Into Mexico and Strengthens Agreement With ZELTIQ(R) Aesthetics
Med school funds are up
Martinsville Bulletin, Inc. P. O. Box 3711 204 Broad Street Martinsville, Virginia 24115 276-638-8801 Toll Free: 800-234-6575
Tuesday, October 2, 2012
By ASHLEY JACKSON - Bulletin Staff Writer
Since launching the Shackelford Campaign to build a medical school in the area, $104,000 has been collected in donations as of last week, according to Noel Boaz, president of Integrative Centers for Science and Medicine (ICSM) in Martinsville.
Read the original:
UB Medical School Names New Chair of Microbiology and Immunology
News Release
Bangs joins the UB School of Medicine and Biomedical Sciences from the University of Wisconsin-Madison Medical School.
Download JPEG
Release Date: September 27, 2012
BUFFALO, N.Y. -- James (Jay) D. Bangs, PhD, professor of medical microbiology and immunology at the University of Wisconsin-Madison Medical School and an expert in the cell biology of the agent that causes African sleeping sickness, has been appointed the Grant T. Fisher Professor and Chair of the Department of Microbiology and Immunology at the University at Buffalo School of Medicine and Biomedical Sciences.
The announcement brings to nine the number of new chairs and chair-level appointees recruited by Michael E. Cain, MD, UB vice president for health sciences and dean of the UB medical school, in the past four years. These national hires, Cain says, are a critical piece of his strategic vision for the medical school's future.
According to Cain, Bangs rapidly emerged as the top candidate following a comprehensive national search, possessing all the skills needed to advance the UB department and expand its basic research programs in service of UB's 2020 strategic goals. Under Bangs, Cain says, the department will enhance the excellence of its research enterprise, undergraduate and graduate student education and mentored research training programs.
Bangs succeeds J. Iain Hay, who has served as chair of the Department of Microbiology and Immunology for 20 years.
A faculty member and trainer for the microbiological doctoral training program at UW, and a member of its Center for Research and Training in Parasitic Diseases, Bangs will join UB in January 2013.
He conducts research on African trypanosomes, one-celled parasites transmitted by the tsetse fly, which cause African sleeping sickness in humans, a fatal disease that is reemerging throughout sub-Saharan Africa.
Here is the original post:
UB Medical School Names New Chair of Microbiology and Immunology
Liberty Bank plans branch office near Southington YMCA
SOUTHINGTON A Liberty Bank branch is planned for the empty lot at 30-60 N. Main St. near the YMCA.
Joe Wren, a professional engineer with Indigo Land Designs, said Liberty Bank has plans for a 2,100-square-foot building with a two-lane drive-through. The bank is scheduled to open in late spring.
The Planning and Zoning Commission unanimously approved the plans last month.
Commission Chairman Michael DelSanto said hes not concerned about the two-lane drive-through causing traffic problems on North Main Street.
They situated the drive-through canopy in a way that theres not going to be congestion as people leave, DelSanto said. Therere always concerns about traffic.
Drive-through customers will exit onto High Street across from the YMCA, according to DelSanto.
Wren told commission members the new building would leave room for people to see a mural painted on the side of the adjacent building.
Commission Vice Chairman Paul Chaplinsky said he was pleased with Liberty Banks plans. The look of the brick and stone bank will complement the rest of the North Main Street streetscape, he said. Town officials say they are trying to create a unified aesthetic for downtown Southington.
Its a really nice fit, Chaplinsky said.
That area of North Main Street is slated for a number of changes as the YMCA continues with its expansion plans, although uncertainty over the brick Olney house has delayed the building of a parking lot. A court injunction has blocked demolition of the house until January.
See original here:
Liberty Silver to Participate in 2012 Toronto Resource Investment Conference
TORONTO, ONTARIO--(Marketwire - Sep 27, 2012) - Liberty Silver Corp. (LSL.TO)(LBSV) ("Liberty Silver" or the "Company") invites shareholders and interested parties to visit the Company at the 2012 Toronto Resource Investment Conference taking place at the Sheraton Centre Toronto, 123 Queen Street West, on September 27th and September 28th, 2012.
Members of Liberty Silver''s senior management team will be available at Booth 910 to discuss recent activities.
About Liberty Silver Corp.
Liberty Silver Corp. is focused on exploring and developing mineral properties located in North America. The Company is led by a skilled, experienced, management team and board of directors with significant experience managing exploration, development and mining projects. The Company is committed to creating value for its shareholders by advancing its current projects utilizing its mitigated risk approach to production, developing new resources on its current properties, and by acquiring new properties that have the potential to increase their resource base. The Trinity Silver project, located in Pershing County, Nevada is the Company''s flagship project. Liberty Silver has the right to earn a joint venture interest in the 10,476 acre Trinity property from Renaissance Gold Inc. pursuant to the terms of an earn in agreement.
Go here to read the rest:
Liberty Silver to Participate in 2012 Toronto Resource Investment Conference
Nearing 60, Lady Liberty stands where big orange once loomed
Sometimes extremely visible parts of our landscape become almost invisible to our eyes, as we drive past them daily. Over many seasons and many years, we tend to take our landmarks for granted.
Orlando's miniature Statue of Liberty offers just one example. Perched on a pedestal across from Lake Ivanhoe, Lady Liberty holds her torch aloft as drivers zoom by her on their way to Interstate 4.
She stands at North Magnolia and North Orange avenues and gets noticed mostly during the pro basketball season, when she's occasionally adorned in an Orlando Magic jersey.
But the statue didn't escape the curiosity of reader Patricia Lockwood of Orlando. It's been there ever since she could remember, Lockwood wrote in a recent email 20 years at least, she thought.
"When was it put there?" Lockwood asked. How did it come about?
Looking good at almost 60
Part of the story appears on a plaque near the statue, and it was fun to find other tidbits in Sentinel files and in Steve Rajtar's "Guide to Historic Orlando" (The History Press, 2006).
Our Lady Liberty, all 8 feet 4 inches of her, has watched over her busy intersection for almost 60 years. She was dedicated Nov. 11, 1953 years before Interstate 4 came through Orlando in the early 1960s.
The statue was one of about 200 such replicas installed across the nation in the 1950s through a Boy Scout program called "Strengthening the Arm of Liberty," Rajtar writes. The program was part of the Scouts' 40th anniversary celebrations.
Visit link:
Nearing 60, Lady Liberty stands where big orange once loomed
Liberty Creek Vineyards and Grammy(R)-Nominated Country Artist David Nail Team up to Support Operation Gratitude
MODESTO, Calif., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Liberty Creek Vineyards and GRAMMY(R)-nominated country artist David Nail have partnered with Operation Gratitude to help servicemen and servicewomen this holiday season with "Tunes for Troops," a program that provides music for care packages to U.S. troops serving overseas. The program kicks off in October and will run through the end of the year. To express their gratitude, Liberty Creek Vineyards will:
"Here at Liberty Creek Wines, we want our troops to know that we appreciate the sacrifices they are making each and every day, especially during the holiday season," says Will Purvis, Brand Manager, Liberty Creek Vineyards. "It's our privilege to partner with Operation Gratitude and David Nail, to help provide some holiday cheer during a difficult time to be away from loved ones."
"I'm honored to be a part of Liberty Creek's Operation Gratitude program," said David Nail when asked about his participation in the program. "It is humbling and inspiring that my music can be a part of sending care packages to the troops."
Operation Gratitude sends care packages and letters personally addressed to U.S. Service Members, including those who have been wounded while they are recovering in transition units.
"We are delighted to receive this support from Liberty Creek Wines and David Nail, and we believe the CDs will make our care packages even more meaningful," says Carolyn Blashek, Founder of Operation Gratitude. "Country music speaks to themes that reinforce the simple pleasures in life--home, friends, family and loved ones, which can be comforting to a Service Member who is far from home, especially during the holidays."
For more information about Liberty Creek Wines and their program to support Operation Gratitude, please visit http://www.LibertyCreekWine.com
Media Contact: Mary Healy, Source Marketing, 203.682.0910 or healy@source-marketing.com
About Liberty Creek Wine
The heritage of Liberty Creek Vineyards is rooted in the rich soils of California, where our grapes are carefully selected for their quality and authentic varietal character. Liberty Creek offers eight great-tasting and affordable wines in a vibrant, fruit-forward portfolio: Chardonnay, Merlot, Cabernet Sauvignon, White Zinfandel, Sweet Red, Pinot Grigio, Pinot Noir, and New Chocolate Red Wine. We support those who find value in tradition, yet stay true to themselves!
For more information about Liberty Creek, please visit http://www.libertycreekwine.com
Read more here:
New Liberty Feasibility Study confirms strong financial returns
TSX: AUE AIM: AUE
TORONTO , Oct. 1, 2012 /CNW/ - Aureus Mining Inc. ("Aureus" or the "Company") is pleased to announce the results of its NI43-101 compliant Feasibility Study ("FS") for its New Liberty Project in Liberia ("New Liberty" or "the Project"). The FS outlines an economically viable and robust gold project based on an average gold price of US$1,400/oz. New Liberty will be Liberia's first commercial gold mine and Aureus' first mine in its highly prospective 546km2 total licence area.
The main conclusions from the FS demonstrate a pre-tax IRR of 37% at an average gold price of US$1,400/oz, average annual production of 120,000oz per annum over the first four years at 3.7g/t head grade, with initial capital costs of US$140m.
In completing the FS Aureus was assisted by AMC Consultants (UK) Limited ("AMC"), DRA Mineral Projects (Pty) Ltd ("DRA"), MDS Ltd ("MDS"), Golder Associates Ghana Ltd ("Golder") and Digby Wells (Pty) Ltd ("Digby Wells"). The FS has been completed to within a 10% cost accuracy based on firm tenders received from suppliers and contractors.
Key highlights of the FS include:
David Reading , Chief Executive Officer of Aureus, commented:
"We are delighted to be able to announce the results from the New Liberty Feasibility Study, which clearly illustrates the technical and financial robustness of the Project. This is a major milestone for the Company and Liberia , as New Liberty will become the country's first commercial gold mine. This will not only generate wealth for Liberia and Aureus' shareholders, but also provide significant employment and the opportunity for ancillary businesses in Grand Cape Mount County, western Liberia ."
"We believe we are still capable of improving the robust economics of the Project further through a number of initiatives. These opportunities include conversion of Inferred Resources through drilling and optimizing infrastructure, plant layout and conditions for gold recovery. Once this work is complete we intend to move quickly to mine building and production phases."
"Aureus Mining remains on track to fulfil its objectives set out during its listing in April 2011: to bring New Liberty into production quickly, to become the first commercial gold mine in Liberia and invest the consequent cash flow into developing the high potential of the remainder of the licence area, with Aureus growing organically into a west African focussed mid-tier gold producer."
A presentation for investors and analysts will take place at 9:00am BST on Monday 1 October 2012 at the office of Buchanan at 107 Cheapside, London , EC2V 6DN. Participation will also be available by webcast or conference call with the following details:
Read this article:
New Liberty Feasibility Study confirms strong financial returns
Harris Corporation Introduces Liberty-Radio Control Equipment for Air Traffic Control Communications
WASHINGTON & GATINEAU, QC, Canada--(BUSINESS WIRE)--
Harris Corporation (HRS), an international communications and information technology company, is introducing its Liberty-Radio Control Equipment (RCE) a flexible gateway product that provides aviation authorities with the next generation of integrated radio control, network routing, and circuit adaptation solutions. The announcement was made during the 57th Annual Air Traffic Control Association Conference and Exposition being held October 1-3 at the Gaylord National Resort and Conference Center in Washington, DC.
Capable of emulating any radio link and broadcasting it over a variety of transmission mediums, the Liberty-RCE will enable communications in harsh conditions and in isolated environments where digital service is typically scarce and reliance on legacy links and older analog technology is still required.
The Liberty-RCE is capable of totally reshaping a network and offers unparalleled flexibility, allowing fluctuations in network traffic and demands on operations to be easily managed. The system allows for the operation and compression of up to six radios per chassis into a single 64 kbps link. The Liberty-RCE supports Split Site Operations as well as Dual Control Site Operations whereby frequencies from two voice communication control system (VCCS) sites (local or remote) can simultaneously access the same radio resources.
A commercial-off-the-shelf device, the Liberty-RCE was specifically engineered to multiplex voice and data signals transmitted between air traffic control (ATC) facilities and deployed radios over satellite, traditional telecommunications links, or newer topologies like Internet Protocol (IP). The Liberty-RCE will facilitate the transmission of data services including digital voice, legacy analog voice, SatCom, datalink, ADS-B, TIS-B, FIS-B, and is interoperable with any brand of VCCS or ATC radio.
The Liberty-RCEs compact 3U chassis offers a sophisticated, fully redundant architecture that ensures system reliability and offers exceptionally high availability to meet any critical communications requirement. The system is also configured with redundant power supplies that can operate in AC or a combination of AC/DC.
Harris Liberty-RCE provides authorities with an opportunity to take advantage of their existing infrastructure by extending investments made and allowing them to ease into new technologies at their own pace and as network standards evolve, said John O'Sullivan, vice president, Mission Critical Networks, Harris Government Communications Systems. Whether deployed in a network operations center or in a remote location, the Liberty-RCE provides aviation authorities with a cost-effective, scalable and highly reliable communications solution.
Recently, the Liberty-RCE was selected by the Federal Aviation Administration (FAA) as an interim solution after they encountered technical issues operating legacy RCE while deploying a remote air/ground communications facility on the oil platform Independence Hub in the Gulf of Mexico.
About Harris Corporation
Harris is an international communications and information technology company serving government and commercial markets in more than 125 countries. Headquartered in Melbourne, Florida, the company has approximately $5.5 billion of annual revenue and about 15,000 employees including 6,000 engineers and scientists. Harris is dedicated to developing best-in-class assured communications products, systems and services. Additional information about Harris Corporation is available at harris.com.
Read the original here:
Harris Corporation Introduces Liberty-Radio Control Equipment for Air Traffic Control Communications